Calcification after myocardial infarction is independent of amniotic fluid stem cell injection.
Ischemic heart disease remains one of the most common causes of mortality in developed countries. Recently, stem cell therapy is being considered for treating ischemic heart diseases. On the other hand, there has been evidence of chondro-osteogenic mass formation after stem cell injection in the heart. In a recent publication, Chiavegato et al. (J Mol Cell Cardiol. 42 (2007) 746-759) has suggested that amniotic fluid-derived stem (AFS) cells cause chondro-osteogenic masses in the infarcted heart. The goal of the current study was to further examine the formation of such masses, specifically, the role of AFS cells in this process. Our results confirm the presence of similar bone-like masses in the left ventricular wall of infarcted rats; however, this phenomenon occurred independent of AFS cell injection into the myocardium. Moreover, AFS cell injection did not increase the presence of chondro-osteogenic masses. Echocardiographic analysis of large infarctions in rats frequently revealed the presence of echogenic structures in the left ventricular wall. We further demonstrated a significant relationship between the infarction size and chondro-osteogenic formation and subsequent decrease in cardiac function. Collectively, our study indicates that chondro-osteogenic differentiation can take place in infarcted rat heart independent of cell injection. These results have significant implications for future design and testing of stem cell therapy for treatment of cardiac muscle diseases.
Delo
Dawn M
DM
Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA. dawn.delo@gmail.com
Guan
Xuan
X
Wang
Zhan
Z
Groban
Leanne
L
Callahan
Michael
M
Smith
Tom
T
Sane
David C
DC
Payne
R Mark
RM
Atala
Anthony
A
Soker
Shay
S
D000653:Amniotic Fluid; D000818:Animals; D002114:Calcinosis / Q000209:etiology* / Q000473:pathology*; D053686:Fetal Stem Cells; D006801:Humans; D009203:Myocardial Infarction / Q000473:pathology* / Q000628:therapy*; D051381:Rats; D011923:Rats, Nude; D017207:Rats, Sprague-Dawley; D033581:Stem Cell Transplantation / Q000009:adverse effects*
Nat Biotechnol. 2005 Jul;23(7):845-56
16003373
J Mol Cell Cardiol. 2007 Apr;42(4):746-59
17300799
Endocrinology. 2003 Jun;144(6):2214-9
12746277
Stem Cells. 2007 Mar;25(3):589-601
17124006
Arch Intern Med. 2007 May 28;167(10):989-97
17533201
Circ Res. 2005 May 13;96(9):930-8
15890980
Physiol Genomics. 2007 Jan 17;28(2):203-12
16926270
Nat Biotechnol. 2007 Jan;25(1):100-6
17206138
Circ Res. 2009 Mar 27;104(6):733-41
19197075
Virchows Arch. 2006 May;448(5):630-8
16211391
Nature. 2004 Apr 8;428(6983):668-73
15034594
Coron Artery Dis. 2008 Aug;19(5):327-35
18607170
J Bone Joint Surg Am. 2009 Mar 1;91(3):652-63
19255227
Stem Cells. 2009 Jan;27(1):150-6
18832590
Nature. 2008 Feb 21;451(7181):937-42
18288183
Blood. 2007 Aug 15;110(4):1362-9
17483296
Circ Res. 2008 Nov 7;103(10):1058-71
18988903
Stem Cells. 2006 Mar;24(3):772-80
16195418
Eur J Cardiothorac Surg. 2006 Jan;29(1):50-5
16337396
J Clin Invest. 2005 Mar;115(3):572-83
15765139
Cell Transplant. 2006;15(5):389-97
16970281
Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):208-16
17951319
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4530-5
17360558
Stem Cells. 2008 Mar;26(3):638-45
18079433
Nat Biotechnol. 2007 Sep;25(9):1015-24
17721512
Eur Heart J. 2005 Aug;26(15):1551-6
15728646
J Appl Physiol (1985). 2007 Jun;102(6):2104-11
17347379
Circulation. 2004 Jun 29;109(25):3154-7
15197139